<DOC>
	<DOCNO>NCT00053820</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth tumor cell . Interleukin-2 may stimulate person 's white blood cell kill tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining interferon alfa interleukin-2 fluorouracil may kill tumor cell . It yet know whether interferon alfa effective without interleukin-2 fluorouracil treat metastatic kidney cancer . PURPOSE : Randomized phase III trial compare effectiveness interferon alfa combine interleukin-2 fluorouracil interferon alfa alone treat patient advanced metastatic kidney cancer .</brief_summary>
	<brief_title>Interferon Alfa With Without Interleukin-2 Fluorouracil Treating Patients With Advanced Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare progression-free overall survival patient advance metastatic renal carcinoma treat interferon alfa without interleukin-2 fluorouracil . - Compare toxicity regimens patient . - Assess quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients randomize 1 2 treatment arm . - Arm I ( Interferon alfa monotherapy ) : Patients receive interferon alfa subcutaneously ( SC ) day 1 , 3 , 5 . Treatment continue weekly least 9 week absence disease progression unacceptable toxicity . - Arm II ( Interferon alfa , interleukin-2 , fluorouracil combination therapy ) : Patients receive interferon alfa SC day 1 week 1 4 day 1 , 3 , 5 week 2 , 3 , 5 , 6 , 7 , 8 . Patients also receive interleukin-2 SC twice daily day 3-5 week 1 4 daily day 1 , 3 , 5 week 2 3 . Patients receive fluorouracil IV day 1 week 5-8 . Treatment repeat every 10 week 2 course absence disease progression unacceptable toxicity . Quality life assess baseline , 9 , 19 , 26 week , 8 month . Patients follow 8 , 10 , 12 month , every 4 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 670 patient ( 335 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Advanced metastatic disease require treatment Measurable disease ( single bone lesion include ) No brain metastasis PATIENT CHARACTERISTICS : Age 18 81 Performance status WHO 01 Life expectancy More 12 week Hematopoietic WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic Not specify Renal Not specify Cardiovascular No myocardial infarction within past 6 month No unstable angina pectoris Other Not pregnant nursing Fertile patient must use effective contraception least 6 month study participation No concurrent disease prior malignancy would preclude study treatment comparisons No concurrent active infection require antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy Chemotherapy No prior chemotherapy Endocrine therapy No prior endocrine therapy No concurrent corticosteroid Radiotherapy At least 4 week since prior radiotherapy Surgery Prior resection primary tumor recommend require No prior major organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>